Halozyme Therapeutics, Inc. announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme’s ENHANZE drug delivery technology, a recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE for a total of six targets, including for the neonatal Fc receptor (FcRn) target.    VYVGART Hytrulo, ar...